Page last updated: 2024-12-06

difloxacin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Difloxacin is a synthetic fluoroquinolone antibiotic that inhibits bacterial DNA gyrase. It is used to treat a variety of bacterial infections, including urinary tract infections, respiratory tract infections, and skin infections. The synthesis of difloxacin involves a multi-step process that begins with the condensation of a substituted aniline with a substituted benzoyl chloride. The resulting amide is then reacted with a substituted piperazine to form the final product. Difloxacin is a broad-spectrum antibiotic that is effective against both Gram-positive and Gram-negative bacteria. It is also effective against some atypical bacteria, such as Mycoplasma pneumoniae and Chlamydia trachomatis. Difloxacin is well-absorbed from the gastrointestinal tract and is widely distributed throughout the body. It is primarily excreted in the urine. Difloxacin is generally well-tolerated, but it can cause side effects such as nausea, vomiting, diarrhea, and headache. Difloxacin is studied to understand its effectiveness against specific bacterial infections, to explore its potential for treating resistant bacterial strains, and to investigate its safety and efficacy in different patient populations.'

difloxacin: RN & structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

difloxacin : A quinolone that is pefloxacin in which the ethyl group at position 1 of the quinolone has been replaced by a p-fluorophenyl group. A broad-spectrum antibiotic effective against both Gram-positive and Gram-negative bacteria, it is used (usually as the monohydrochloride salt) for the treatment of bacterial infections in dogs. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID56206
CHEMBL ID6259
CHEBI ID4537
SCHEMBL ID148765
MeSH IDM0136497

Synonyms (49)

Synonym
difloxacin [inn]
6-fluoro-1-(4-fluorophenyl)-7-(4-methyl-1-piperazinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
STK618168
6-fluoro-1-(4-fluorophenyl)-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
LS-14845
AKOS005551754
6-fluoro-1-(4-fluorophenyl)-1,4-dihydro-7-(4- methyl-1- piperazinyl)-4-oxo-3- quinolinecarboxylic acid
a 56619
3-quinolinecarboxylic acid, 6-fluoro-1-(4-fluorophenyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-
6-fluoro-1-(4-fluorophenyl)-7-(4-methylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid
difloxacin
98106-17-3
AC-12060
pulsaflox
CHEMBL6259
dicural
chebi:4537 ,
D07828
difloxacin (inn)
6-fluoro-1-(4-fluorophenyl)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
6-fluoro-1-(4-fluorophenyl)-7-(4-methylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid;difluoxacin hydrochloride
A845811
A843794
6-fluoro-1-(4-fluorophenyl)-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid
6-fluoranyl-1-(4-fluorophenyl)-7-(4-methylpiperazin-1-yl)-4-oxidanylidene-quinoline-3-carboxylic acid
BBL010805
unii-5z7oo9fnfd
5z7oo9fnfd ,
FT-0624916
3-quinolinecarboxylic acid, 6-fluoro-1-(4-fluorophenyl) 1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-
difloxacin [ema epar veterinary]
difloxacin [mi]
6-fluoro-1-(p-fluorophenyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid
SCHEMBL148765
DTXSID5048348
NOCJXYPHIIZEHN-UHFFFAOYSA-N
zinc04099034
AB00923781_02
AB00923781_04
rkl10076
A858583
Q5275450
DB11511
3-quinolinecarboxylic acid,6-fluoro-1-(4-fluorophenyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-
BCP33408
gtpl10801
4-(4-hydroxy-4-p-tolylpiperidin-1-yl)-1-phenylbutan-1-one
CS-0081346
HY-121272

Research Excerpts

Overview

Difloxacin is a new quinolone antimicrobial agent with in vitro activity against both Neisseria gonorrhoeae and Chlamydia trachomatis.

ExcerptReferenceRelevance
"Difloxacin is a new quinolone antimicrobial agent with in vitro activity against both Neisseria gonorrhoeae and Chlamydia trachomatis and a long (26-h) half-life. "( Evaluation of difloxacin in the treatment of uncomplicated urethral gonorrhea in men.
Benes, S; Cummings, M; Draft, K; McCormack, WM; Smith, BL, 1989
)
2.08

Actions

ExcerptReferenceRelevance
"Difloxacin showed lower activity against most isolates at pH 8.0 as compared to the activity at pH 7.4 and 6.8."( In vitro activities of A-56619 (difloxacin) and A-56620, two aryl fluoroquinolones.
Dibb, WL; Digranes, A, 1988
)
1.28

Treatment

ExcerptReferenceRelevance
"Treatment with difloxacin was associated with the eradication of C."( Evaluation of difloxacin in the treatment of uncomplicated urethral gonorrhea in men.
Benes, S; Cummings, M; Draft, K; McCormack, WM; Smith, BL, 1989
)
0.98

Pharmacokinetics

The plasma difloxacin concentration-time curve was best described by a two-compartment open model, with a distribution half-life (t(1/2alpha)) of 0. Mean half- life for dif loxacins administered IV, IM, and IG was 2.

ExcerptReferenceRelevance
"8 h; the mean half-life for all subjects was 25."( Difloxacin metabolism and pharmacokinetics in humans after single oral doses.
Granneman, GR; Shu, VS; Snyder, KM, 1986
)
1.71
" Pharmacokinetic properties of difloxacin have been studied in pig and chicken after intravenous and oral administration."( Pharmacokinetic properties and oral bioavailabilities of difloxacin in pig and chicken.
Endo, T; Inui, T; Matsushita, T; Taira, T, 1998
)
0.83
" Time of maximum plasma concentration (Tmax) was similar for MAR and DIF; Tmax occurred earlier for ENR and later for CIP."( Comparison of fluoroquinolone pharmacokinetic parameters after treatment with marbofloxacin, enrofloxacin, and difloxacin in dogs.
Evans, EI; Frazier, DL; Thompson, L; Trettien, A, 2000
)
0.52
" Pharmacokinetic parameters were calculated by noncompartmental methods."( Comparative serum pharmacokinetics of the fluoroquinolones enrofloxacin, difloxacin, marbofloxacin, and orbifloxacin in dogs after single oral administration.
Heinen, E, 2002
)
0.55
"The pharmacokinetic properties of difloxacin following intravenous (i."( Pharmacokinetics of difloxacin in goats.
Abd El-Aty, AM; Atef, M; el-Banna, HA; Goudah, A, 2002
)
0.92
" Pharmacokinetic parameters of difloxacin were analyzed."( Pharmacokinetics of difloxacin after intravenous, intramuscular, and intragastric administration to horses.
Ayala, I; Cárceles, CM; Escudero, E; Fernández-Varón, E; Marín, P; Martos, N, 2006
)
0.94
" aureus from different european countries was performed in order to compute the main pharmacodynamic surrogate markers."( Disposition kinetics and pharmacokinetics--pharmacodynamic integration of difloxacin against Staphylococcus aureus isolates from rabbits.
Cárceles, CM; Fernández-varón, E; García-Martínez, JD; Marín, P; Montes, A; Sotillo, J; Vancraeynest, D, 2008
)
0.58
"The purpose of this study was to examine the allometric analyses of marbofloxacin, moxifloxacin, danofloxacin and difloxacin using pharmacokinetic data from the literature."( Allometric scaling of marbofloxacin, moxifloxacin, danofloxacin and difloxacin pharmacokinetics: a retrospective analysis.
Cox, SK, 2007
)
0.79
" Plasma concentration profiles were analyzed by a compartmental pharmacokinetic method."( Pharmacokinetics of difloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications.
Chen, ZL; Ding, HZ; Huang, XH; Yang, GX; Zeng, ZL, 2008
)
0.67
" Minimum inhibitory concentrations of difloxacin against 14 strains of Staphylococcus aureus isolated from mastitic goats' milk in Spain were determined to compute pharmacodynamic surrogate markers."( Pharmacokinetics and milk penetration of difloxacin after a long-acting formulation for subcutaneous administration to lactating goats.
Cárceles, CM; Escudero, E; Fernández-Varón, E; Marín, P; Ramírez, MJ, 2010
)
0.9

Compound-Compound Interactions

ExcerptReferenceRelevance
" Therefore, a new liquid-liquid extraction method combined with HPLC-MS/MS for the detection of marbofloxacin, ciprofloxacin, enrofloxacin and difloxacin in chicken feces was developed."( Determination of fluoroquinolones in chicken feces - a new liquid-liquid extraction method combined with LC-MS/MS.
Hamscher, G; Janusch, F; Mohring, SA; Scherz, G, 2014
)
0.6

Bioavailability

The in vitro plasma protein binding of difloxacin ranged from 28-43% and the absolute bioavailability following IM administration was 93.

ExcerptReferenceRelevance
"45% and the systemic bioavailability was 95."( Disposition kinetics of difloxacin in rabbit after intravenous and intramuscular injection of Dicural.
Abd El-Aty, AM; Goudah, A; Ismail, M; Shimoda, M, 2005
)
0.64
" After IM administration, the absolute mean +/- SD bioavailability was 95."( Pharmacokinetics of difloxacin after intravenous, intramuscular, and intragastric administration to horses.
Ayala, I; Cárceles, CM; Escudero, E; Fernández-Varón, E; Marín, P; Martos, N, 2006
)
0.66
" The in vitro plasma protein binding of difloxacin ranged from 28-43% and the absolute bioavailability following IM administration was 93."( Pharmacokinetics and intramuscular bioavailability of difloxacin in dromedary camels (Camelus dromedarius).
Abo-El-Sooud, K; Goudah, A, 2009
)
0.87
" Oral bioavailability was found to be 68."( Plasma disposition and tissue depletion of difloxacin and its metabolite sarafloxacin in the food producing animals, chickens for fattening.
Anadón, A; Ares, I; Castellano, V; Gamboa, F; Martínez, M; Martínez, MA; Martínez-Larrañaga, MR; Ramos, E; Suárez, FH, 2011
)
0.63
" The calculated bioavailability of difloxacin was 68."( Pharmacokinetics of difloxacin in olive flounder Paralichthys olivaceus at two water temperatures.
Chang, ZQ; Gai, CL; Li, J; Li, JT; Sun, M; Zhao, FZ, 2014
)
1
" The systemic bioavailability of difloxacin following oral administration was 86."( Pharmacokinetics of difloxacin in healthy and E. coli-infected broiler chickens.
Abo El-Ela, FI; El-Banna, HA; El-Gendy, AA; Radi, AM; Tohamy, MA, 2014
)
1.01

Dosage Studied

The earliest morphologic and biochemical changes induced in articular-epiphyseal cartilage complexes by difloxacin, a fluoroquinolone, were investigated. 27 3-month-old Beagle dogs that were dosed orally with the drug at 300 mg/kg body weight per day.

ExcerptRelevanceReference
" The earliest morphologic and biochemical changes induced in articular-epiphyseal cartilage complexes by difloxacin, a fluoroquinolone, were investigated in 27 3-month-old Beagle dogs that were dosed orally with the drug at 300 mg/kg body weight per day."( Morphologic and biochemical changes in articular cartilages of immature beagle dogs dosed with difloxacin.
Burkhardt, JE; Carlton, WW; Hill, MA, 1992
)
0.72
"The ultrastructural features of quinolone-induced arthropathy were studied in the humeral and femoral heads of nine skeletally immature Beagle dogs (3 months old) that were dosed orally with difloxacin at 300 mg/kg body weight and euthanatized 24, 36, or 48 hours later in groups of three."( Ultrastructural changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone.
Burkhardt, JE; Carlton, WW; Hill, MA; Turek, JJ, 1992
)
0.7
"The fluoroquinolones, temafloxacin, sarafloxacin, and difloxacin, are determined in the bulk drug substances and in a variety of dosage form using high-performance liquid chromatography (HPLC)."( Determination of temafloxacin, sarafloxacin, and difloxacin in bulk drug and dosage forms by high-performance liquid chromatography.
Bauer, JF; Elrod, L; Fornnarino, JR; Heathcote, DE; Krogh, SK; Linton, CL; Norris, BJ; Quick, JE, 1990
)
0.78
"The histologic and histochemical features of quinolone-induced arthropathy were studied using 14 skeletally immature Beagle dogs (3 to 4 months old) dosed orally with difloxacin at 300 mg/kg body weight once daily for 1, 2, 5, or 7 days."( Histologic and histochemical changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone.
Burkhardt, JE; Carlton, WW; Hill, MA; Kesterson, JW, 1990
)
0.69
" Based on the single-dose pharmacokinetic parameters determined, multiple dosage regimens were recommended as: a dosage of 5 mg/kg given intramuscularly every 24 h in pigs, or administered orally every 24 h at the dosage of 10 mg/kg in broilers, can maintain effective plasma concentrations with bacteria infections, in which MIC(90) are <0."( Pharmacokinetics of difloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications.
Chen, ZL; Ding, HZ; Huang, XH; Yang, GX; Zeng, ZL, 2008
)
0.67
" Plasma and milk elimination half-lives after P407-CMC dosing were 35."( Pharmacokinetic and milk penetration of a difloxacin long-acting poloxamer gel formulation with carboxy-methylcellulose in lactating goats.
Cárceles, CM; Escudero, E; Fernández-Varón, E; Marín, P; Ramírez, MJ, 2011
)
0.63
" The influence of three frequently used antibiotics, copper dosed as CuSO(4), sulfadiazine (SDZ), and difloxacin (DIF), on the anaerobic digestion process of pig manure was studied in semi-continuous experiments."( Short term effects of copper, sulfadiazine and difloxacin on the anaerobic digestion of pig manure at low organic loading rates.
Clemens, J; Dong, R; Guo, J; Ostermann, A; Siemens, J, 2012
)
0.85
" Feces of chickens treated with an enrofloxacin dosage of 10mg/kg bodyweight revealed maximum enrofloxacin and ciprofloxacin concentrations of 61."( Determination of fluoroquinolones in chicken feces - a new liquid-liquid extraction method combined with LC-MS/MS.
Hamscher, G; Janusch, F; Mohring, SA; Scherz, G, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antibacterial drugA drug used to treat or prevent bacterial infections.
Mycoplasma genitalium metaboliteAny bacterial metabolite produced during a metabolic reaction in Mycoplasma genitalium.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (7)

ClassDescription
quinolone
N-alkylpiperazine
N-arylpiperazine
quinolone antibioticAn organonitrogen heterocyclic antibiotic whose structure contains a quinolone or quinolone-related skeleton.
fluoroquinolone antibioticAn organonitrogen heterocyclic antibiotic containing a quinolone (or quinolone-like) moiety and which have a fluorine atom attached to the central ring system.
monofluorobenzenesAny member of the class of fluorobenzenes containing a mono- or poly-substituted benzene ring carrying a single fluorine substitutent.
monocarboxylic acidAn oxoacid containing a single carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency3.98110.035520.977089.1251AID504332
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency39.81070.010323.856763.0957AID2662
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency28.18380.251215.843239.8107AID504327
lamin isoform A-delta10Homo sapiens (human)Potency17.78280.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (107)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID30270In vitro antibacterial activity against Acinetobacter CMX 6691987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID163921Minimum inhibition concentration in vitro determined against Pseudomona aeruginosa 50071985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Synthesis and structure-activity relationships of novel arylfluoroquinolone antibacterial agents.
AID135327BBB penetration classification2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
AID278262Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS14 acrAB::Kan with GyrA D87G mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID133949In vivo activity against Streptococcus pneumoniae (sc)1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
AID278251Antimicrobial activity against Salmonella enterica serovar Typhimurium CS1 tolC::Kan with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID133823In vivo activity against Escherichia coli (po)1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
AID209567In vitro antibacterial activity against Streptococcus faecium ATCC 80431987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID70799Compound was evaluated for inhibitory activity against Escherichia coli Juhl (in vivo)1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Synthesis and structure-activity relationships of novel arylfluoroquinolone antibacterial agents.
AID67684In vitro antibacterial activity against Enterobacter aerogenes ATCC 130481987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID133947In vivo activity against Pseudomonas aeruginosa (sc)1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
AID209294In vitro antibacterial activity against Streptococcus pyogenes 9301987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID278256Antimicrobial activity against Salmonella enterica serovar Typhimurium CS9 with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID70409In vitro antibacterial activity against Escherichia coli Juhl1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID278250Antimicrobial activity against Salmonella enterica serovar Typhimurium CS1 acrAB::Kan with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278253Antimicrobial activity against Salmonella enterica serovar Typhimurium CS3 gyrA+ with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278249Antimicrobial activity against Salmonella enterica serovar Typhimurium CS1 gyrA+ with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278271Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS38 tolC::Kan with GyrA D87G mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID164555In vitro antibacterial activity against Pseudomonas aeruginosa K799/WT1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID95882Minimum inhibition concentration in vitro determined against Klebsiella pneumoniae 80451985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Synthesis and structure-activity relationships of novel arylfluoroquinolone antibacterial agents.
AID207944In vitro antibacterial activity against Staphylococcus aureus CMX 686B1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID96096In vitro antibacterial activity against Klebsiella pneumoniae 80451987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID736392Antibacterial activity against Pseudomonas stutzeri A1501 by paper disk diffusion method2013Journal of natural products, Jan-25, Volume: 76, Issue:1
Antibacterial and antiplasmodial constituents of Beilschmiedia cryptocaryoides.
AID70800Minimum inhibition concentration in vitro determined against Escherichia coli juhl 1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Synthesis and structure-activity relationships of novel arylfluoroquinolone antibacterial agents.
AID278243Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-3 tolC::Kan with GyrA S83F, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278244Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-4 with GyrA S83F, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278234Antimicrobial activity against Salmonella enterica serovar Typhimurium GyrA S21-1 acrAB::Kan with GyrA S83F mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID207573Minimum inhibition concentration in vitro determined against Staphylococcus aureus CMX 686B1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Synthesis and structure-activity relationships of novel arylfluoroquinolone antibacterial agents.
AID278236Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-2 with GyrA S83F, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278259Antimicrobial activity against Salmonella enterica serovar Typhimurium CS9 tolC::Kan with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID163052Minimum inhibitory concentration against Providencia rettgeri. (M1771)1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
AID209763Minimum inhibitory concentration against Streptococcus pyogenes (C203).1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
AID278266Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS18 acrAB::Kan with GyrA S38F mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278229Antimicrobial activity against Salmonella enterica serovar Typhimurium S21 gyrA+2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID93887Minimum inhibitory concentration against Klebsiella pneumoniae (MGH-2)1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
AID210401Minimum inhibition concentration in vitro determined against Streptococcus pyogenes 9301985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Synthesis and structure-activity relationships of novel arylfluoroquinolone antibacterial agents.
AID66387Minimum inhibition concentration in vitro determined against Enterobacteri aerogenes ATCC 130481985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Synthesis and structure-activity relationships of novel arylfluoroquinolone antibacterial agents.
AID113529In vivo inhibitory activity against Escherichia coli Juhl after peroral administration in mice1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Synthesis and structure-activity relationships of novel arylfluoroquinolone antibacterial agents.
AID278241Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-3 gyrA+ with ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278235Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-1 tolC::Kan with GyrA S83F mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID208310Minimum inhibitory concentration against Streptococcus pneumoniae (SV-1).1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
AID207550Minimum inhibition concentration in vitro determined against Staphylococcus aureus ATCC 6538P1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Synthesis and structure-activity relationships of novel arylfluoroquinolone antibacterial agents.
AID278248Antimicrobial activity against Salmonella enterica serovar Typhimurium CS1 with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID207626Compound is evaluated for cross resistance with DNA gyrase subunit A or B against Staphylococcus aureus 337-113 (norfloxacin-resistant)1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Aromatic dienoyl tetramic acids. Novel antibacterial agents with activity against anaerobes and staphylococci.
AID206205Minimum inhibition concentration in vitro determined against Staphylococcus epidermidis 35191985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Synthesis and structure-activity relationships of novel arylfluoroquinolone antibacterial agents.
AID205531Minimum inhibitory concentration against Staphylococcus aureus (H-228).1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
AID112501In vivio inhibitory activity against Escherichia coli Juhl after subcutaneous administration in mice1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Synthesis and structure-activity relationships of novel arylfluoroquinolone antibacterial agents.
AID205543Minimum inhibitory concentration against Staphylococcus aureus (UC76).1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
AID209248Minimum inhibitory concentration against Streptococcus faecalis (MGH-2).1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
AID207625Compound is evaluated for cross resistance with DNA gyrase subunit A or B against Staphylococcus aureus 730A1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Aromatic dienoyl tetramic acids. Novel antibacterial agents with activity against anaerobes and staphylococci.
AID278252Antimicrobial activity against Salmonella enterica serovar Typhimurium CS3 with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID68506Minimum inhibitory concentration against Enterobacter cloacae. (MA2446).1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
AID278242Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-3 acrAB::Kan with GyrA S83F, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278265Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS18 gyrA+ with GyrA S38F mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID515780Intrinsic solubility of the compound in water2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
QSAR-based solubility model for drug-like compounds.
AID78687Lowest concentration necessary to induce DNA gyrase-mediated cleavage of DNA1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
AID78550Concentration required for 50% inhibition of gyrase.1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
AID278264Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS18 with GyrA S38F mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID209583Minimum inhibition concentration in vitro determined against Streptococcus faecium ATCC 80431985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Synthesis and structure-activity relationships of novel arylfluoroquinolone antibacterial agents.
AID67545Activity against Enterobacter aerogenes2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Search compounds with antimicrobial activity by applying molecular topology to selected quinolones.
AID206215In vitro antibacterial activity against Staphylococcus epidermis 35191987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID278245Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-4 gyrA+ with ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278239Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-2 tolC::Kan with GyrA S83F, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID736393Antibacterial activity against Acinetobacter calcoaceticus DSM 586 by paper disk diffusion method2013Journal of natural products, Jan-25, Volume: 76, Issue:1
Antibacterial and antiplasmodial constituents of Beilschmiedia cryptocaryoides.
AID69470Minimum inhibitory concentration against Escherichia coli (vogel)1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
AID133951In vivo activity against Streptococcus pyogenes (sc)1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
AID133824In vivo activity against Escherichia coli (sc)1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
AID681318TP_TRANSPORTER: increase in Daunorubicin, Adriamycin and Vincristine intracellular accumulation (Daunorubicin: 4 ug/mL, Difloxacin: 62.5 uM) in HL-60/AR cells1995Oncology research, , Volume: 7, Issue:5
Difloxacin reverses multidrug resistance in HL-60/AR cells that overexpress the multidrug resistance-related protein (MRP) gene.
AID207628Compound is evaluated for cross resistance with DNA gyrase subunit A or B against Staphylococcus aureus 45CR-1 (coumermycin resistant)1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Aromatic dienoyl tetramic acids. Novel antibacterial agents with activity against anaerobes and staphylococci.
AID133946In vivo activity against Pseudomonas aeruginosa (po)1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
AID278263Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS14 tolC::Kan with GyrA D87G mutant2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID69469Minimum inhibitory concentration against Escherichia coli (H560)1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
AID736391Antibacterial activity against Serratia plymuthica C48 by paper disk diffusion method2013Journal of natural products, Jan-25, Volume: 76, Issue:1
Antibacterial and antiplasmodial constituents of Beilschmiedia cryptocaryoides.
AID163922Minimum inhibition concentration in vitro determined against Pseudomona aeruginosa K799/WT1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Synthesis and structure-activity relationships of novel arylfluoroquinolone antibacterial agents.
AID278238Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-2 acrAB::Kan with GyrA S83F, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278260Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS14 with GyrA D87G mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278237Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-2 gyrA+ with ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278228Antimicrobial activity against Salmonella enterica serovar Typhimurium S212007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278258Antimicrobial activity against Salmonella enterica serovar Typhimurium CS9 acrAB::Kan with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278240Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-3 with GyrA S83F, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278230Antimicrobial activity against Salmonella enterica serovar Typhimurium S21 acrAB::Kan2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID30551Minimum inhibition concentration in vitro determined against Acinetobacter sp CMX6691985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Synthesis and structure-activity relationships of novel arylfluoroquinolone antibacterial agents.
AID278246Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-4 acrAB::Kan with GyrA S83F, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID222085Minimum inhibitory concentration against gram-negative enterobacteriaceae.1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
AID278267Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS18 tolC::Kan with GyrA S38F mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278261Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS14 gyrA+ with GyrA D87G mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID64912In vitro antibacterial activity against Escherichia coli ATCC 25922.1992Journal of medicinal chemistry, Sep-18, Volume: 35, Issue:19
Synthesis and antibacterial activity of 1-(substituted pyrrolyl)-7-(substituted amino)-6-fluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acids.
AID133948In vivo activity against Streptococcus pneumoniae (po)1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
AID164554In vitro antibacterial activity against Pseudomonas aeruginosa 50071987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID70458Biological activity against Escherichia coli N1HJ JC-2 relative to Norfloxacin.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Three-dimensional structure-activity relationships and receptor mapping of N1-substituents of quinolone antibacterials.
AID201266In vitro antibacterial activity against Staphylococcus aureus ATCC 6538p.1992Journal of medicinal chemistry, Sep-18, Volume: 35, Issue:19
Synthesis and antibacterial activity of 1-(substituted pyrrolyl)-7-(substituted amino)-6-fluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acids.
AID278270Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS38 acrAB::Kan with GyrA D87G mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278247Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-4 tolC::Kan with GyrA S83F, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID133950In vivo activity against Streptococcus pyogenes (po)1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
AID736394Antibacterial activity against Escherichia coli 6r3 by paper disk diffusion method2013Journal of natural products, Jan-25, Volume: 76, Issue:1
Antibacterial and antiplasmodial constituents of Beilschmiedia cryptocaryoides.
AID278231Antimicrobial activity against Salmonella enterica serovar Typhimurium S21 tolC::Kan2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID207627Compound is evaluated for cross resistance with DNA gyrase subunit A or B against Staphylococcus aureus 451989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Aromatic dienoyl tetramic acids. Novel antibacterial agents with activity against anaerobes and staphylococci.
AID278269Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS38 gyrA+ with GyrA D87G mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278233Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-1 gyrA+2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278255Antimicrobial activity against Salmonella enterica serovar Typhimurium CS3 tolC::Kan with GyrA S83F, D87N, parC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID163100Minimum inhibitory concentration against Pseudomonas aeruginosa. (UI-18)1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
AID278268Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS38 with GyrA D87G mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278254Antimicrobial activity against Salmonella enterica serovar Typhimurium CS3 acrAB::Kan with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278257Antimicrobial activity against Salmonella enterica serovar Typhimurium CS9 gyrA+ with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278232Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-1 GyrA S83F mutant2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID207943In vitro antibacterial activity against Staphylococcus aureus ATCC 6538P1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (119)

TimeframeStudies, This Drug (%)All Drugs %
pre-199041 (34.45)18.7374
1990's18 (15.13)18.2507
2000's37 (31.09)29.6817
2010's20 (16.81)24.3611
2020's3 (2.52)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 44.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index44.95 (24.57)
Research Supply Index4.91 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index68.69 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (44.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (5.51%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other120 (94.49%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]